Data for Biguanide iridium(III) complexes with potent antimicrobial activity by Chen, Feng et al.
S1 
 
Biguanide Irdium(III) Complexes with Potent Antimicrobial 
Activity  
 
Feng Chen, John Moat, Daniel McFeely, Guy Clarkson, Ian J. Hands-Portman, Jessica P. 
Furner-Pardoe, Freya Harrison, Christopher G. Dowson and Peter J. Sadler 
 
Supporting Information 
Synthesis of Chelating Ligands L6-L10                                                                             S2 
Preparation of Samples and Antibiotic Standards                                                            S3 
Antibacterial Assays                                                                                                             S3 
Antifungal Assays                                                                                                                 S3 
Cytotoxicity Assays                                                                                                               S4 
Table S1 Crystallographic Data for Complexes 1 and 4                                                        S6 
Table S2. Hydrogen Bond Lengths (Å) and Angles (o) for Complex 1                                S7 
Table S3. Hydrogen Bond Lengths (Å) and Angles (o) for Complex 4                                S7 
Table S4. Antimicrobial Activity of Complexes 1-14 and HPLC retention times                S8 
Table S5. Antibacterial Activity of Complexes 4-10 against S. aureus and S. pyogenes under 
Anaerobic and Aerobic Conditions                                                                                        S9 
Table S6. Selectivity Factors (SF) for Complexes 4-14                                                        S9 
Table S7. Dependence of Antibacterial Activity of Complexes 4-10 on Time of Storage of 
Solutions of Complexes in CAMHB Medium at Various Temperatures for 21 Days          S10 
Table S8. S. aureus Biofilm Disruption by Complexes 4-9                                                  S10 
Table S9. Results of ANOVA                                                                                               S11 
Table S10. MBC/MIC Ratios of for Complexes 1-14                                                             S11 
Figure S1. Elution condition for hydrophobicity measurements by RP-HPLC                    S12 
Figure S2. Plot of retention time versus MICs for complexes 1-4 against MRSA               S12   
Figure S3. Reaction of complex 4 with L-cysteine monitored by 1H NMR                         S13 
Figure S4. Reaction of complex 7 with L-cysteine monitored by 1H NMR                         S14 
Figure S5. Reaction of complexes 4, 7 and 10 with L-cysteine monitored by LC-MS        S15 
Figure S6. LC-MS gradients for identification of [(CpXbiph)Ir(L-Cys)]2
2+                             S15 
Figure S7. pH* dependence 1H NMR  resonances of ligands L5 and L6                             S16 
References                                                                                                                             S17 
 
  
S2 
 
Synthesis of Chelating Ligands L6-L10:  
TolSul-Big-Tol (L6). The ligand was synthesized according to a published literature with 
following modifications:1 A solution of 1-(o-tolyl)biguanide  (360 mg, 1.88 mmol)  in 
dichloromethane (150 mL) was placed in a round bottom flask. A solution of toluenesulfonyl 
chloride (300 mg, 1.58 mmol) in dichloromethane (50 mL) was added slowly via a dropping 
funnel, and the mixture stirred vigorously for 12 h. Solvent was removed on a rotary evaporator 
to give a white solid which was purified on a chromatography column (MeOH/DCM, 
7/93(v/v)). Yield = 294 mg (54 %). 1H NMR (400 MHz, MeOD-d4): δH 2.23 (s, 3H), 2.40 (s, 
3H), 7.19-7.23 (m, 3H), 7.28 (d, J = 6.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 8.2 Hz, 
2H). ESI-MS: Calc for [C16H19N5O2S + Na]
+ 368.1 m/z, found: 368.1 m/z. 
4-(BrCH2)-PhSul-Big-Tol (L7). This ligand was obtained following the above method using 
400 mg of 1-(o-tolyl)biguanide and 470 mg of 4-(bromomethyl)benzene sulfonyl chloride. 
Yield = 252 mg (34%). 1H NMR (400 MHz, DMSO-d6): δH 2.15 (s, 3H), 4.73 (s, 2H), 7.17 (d, 
J = 7.3 Hz, 2H), 7.24 (d, J = 7.0 Hz, 2H), 7.59 (d, J = 8.2 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H). 
ESI-MS: Calc for [C16H18BrN5O2S + H]
+ 446.0 m/z, found: 446.2 m/z. 
4-F-PhSul-Big-Tol (L8). This ligand was obtained following the above method using 400 mg 
of 1-(o-tolyl)biguanide and 340 mg of 4-fluoro-benzenesulfonyl chloride. Yield = 390 mg 
(64%). 1H NMR (400 MHz, MeOD-d4): δH 2.24 (s, 3H), 7.19-7.26 (m, 5H), 7.28 (d, J = 6.6 Hz, 
1H), 7.91-7.94 (m, 4H). ESI-MS: Calc for [C15H16FN5O2S + Na]
+ 372.0 m/z, found: 371.9 m/z. 
4-NO2-PhSul-Big-Tol (L9). This ligand was obtained following the above method using 360 
mg of 1-(o-tolyl)biguanide and 300 mg of 4-nitro-benzenesulfonyl chloride. Yield = 240 mg 
(47%). 1H NMR (400 MHz, DMSO-d6): δH 2.17 (s, 3H), 7.01 (t, J = 6.8 Hz, 1H), 7.26 (dd, J = 
7.6 Hz, 22 Hz, 3H), 8.05 (d, J = 8.4 Hz, 2H), 8.34 (d, J = 3.4 Hz, 2H). ESI-MS: Calc for 
[C15H16N6O4S + H]
+ 377.1 m/z, found: 376.9 m/z. 
Dan-Big-Tol (L10). This ligand was obtained following the above method using 354 mg of 1-
(o-tolyl)biguanide and 300 mg of dansyl chloride. Yield = 251 mg (53%). 1H NMR (400 MHz, 
MeOD-d4): δH 2.05 (s, 3H), 2.86 (s, 6H), 7.11-7.16 (m, 2H), 7.20-7.26 (m, 3H), 7.33 (t, J = 7.9 
Hz, 1H), 7.54 (t, J = 8.3 Hz, 1H), 8.23 (d, J = 6.6 Hz, 1H), 8.41 (d, J = 8.7 Hz, 1H), 8.49 (d, J 
= 8.5 Hz, 1H). ESI-MS: Calc for [C21H24N6O2S + H]
+ 425.1 m/z, found: 425.0 m/z. 
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Summary of Protocols for Experiments Carried out by CO-ADD2 
Preparation of Samples and Antibiotic Standards   
Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative 
and Gram-positive bacteria, respectively. Fluconazole was used as a positive fungal inhibitor 
standard for C. albicans and C. neoformans. The antibiotics were provided in 4 concentrations, 
with 2 above and 2 below its MIC value, and plated into the first 8 wells of column 23 of the 
384-well NBS plates. The quality control (QC) of the assays was determined by the 
antimicrobial controls and the Z’-factor (using positive and negative controls). Each plate was 
deemed to fulfil the quality criteria (pass QC), if the Z’-factor was above 0.4, and the 
antimicrobial standards showed full range of activity, with full growth inhibition at their 
highest concentration, and no growth inhibition at their lowest concentration. 
Antibacterial Assays  
All bacteria were cultured in Cation-adjusted Mueller Hinton Broth (CAMHB) at 37 °C 
overnight. A sample of each culture was then diluted 40-fold in fresh broth and incubated at 37 
°C for 1.5 - 3 h. The resultant mid-log phase cultures were diluted (CFU/mL measured by 
OD600), then added to each well of the compound containing plates, giving a cell density of 5 
× 105 CFU/mL and a total volume of 50 μL. All the plates were covered and incubated at 37 
°C for 18 h without shaking. Inhibition of bacterial growth was determined measuring 
absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate reader. The 
percentage of growth inhibition was calculated for each well, using the negative control (media 
only) and positive control (bacteria without inhibitors) on the same plate as references. The 
significance of the inhibition values was determined by modified Z-scores, calculated using the 
median and MAD of the samples (no controls) on the same plate. Samples with inhibition value 
above 80% and Z-Score above 2.5 for either replicate (n = 2 on different plates) were classed 
as actives. Samples with inhibition values between 50 - 80% and Z-Score above 2.5 for either 
replicate (n = 2 on different plates) were classed as partial actives.  
Antifungal Assays 
Fungi strains were cultured for 3 days on Yeast Extract-Peptone Dextrose (YPD) agar at 30 
°C. A yeast suspension of 1 × 106 to 5 × 106 CFU/mL (as determined by OD530) was prepared 
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from five colonies. The suspension was subsequently diluted and added to each well of the 
compound-containing plates giving a final cell density of fungi suspension of 2.5 × 103 
CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 35 °C for 24 h 
without shaking. Growth inhibition of C. albicans was determined measuring absorbance at 
530 nm (OD530), while the growth inhibition of C. neoformans was determined measuring the 
difference in absorbance between 600 and 570 nm (OD600-570), after the addition of resazurin 
(0.001% final concentration) and incubation at 35 °C for additional 2 h. The absorbance was 
measured using a Biotek Synergy HTX plate reader. The percentage of growth inhibition was 
calculated for each well, using the negative control (media only) and positive control (fungi 
without inhibitors) on the same plate. The significance of the inhibition values was determined 
by modified Z-scores, calculated using the median and MAD of the samples (no controls) on 
the same plate. Samples with inhibition value above 80% and Z-Score above 2.5 for either 
replicate (n = 2 on different plates) were classed as actives. Samples with inhibition values 
between 50 - 80% and Z-Score above 2.5 for either replicate (n = 2 on different plates) were 
classed as partial actives. 
Cytotoxicity Assays  
Growth inhibitions of HEK-293 and RBC cells were determined measuring fluorescence at ex: 
530/10 nm and em: 590/10 nm (F560/590), after the addition of resazurin (25 μg/mL final 
concentration) and incubation at 37 °C and 5% CO2, for additional 3 h. The fluorescence was 
measured using a Tecan M1000 Pro monochromator plate reader. The percentage of growth 
inhibition was calculated for each well, using the Negative Control (media only) and Positive 
Control (cell culture without inhibitors) on the same plate. 
CC50 (Concentration at 50% Cytotoxicity against HEK-293) were calculated by curve fitting 
the inhibition values vs. log (concentration) using Sigmoidal dose-response function, with 
variable values for bottom, top and slope. The curve fitting is implemented using Pipeline 
Pilot's dose-response component (giving similar results to similar tools such as GraphPad's 
Prism and IDBS's XlFit). Any value with > indicates a sample with no activity (low DMax 
value) or samples with CC50 values above the maximum tested concentration (higher DMax 
value). 
HC50 (Concentration at 50% haemolytic activity, human red blood cells) were calculated by 
curve fitting the inhibition values vs. log (concentration) using Sigmoidal dose-response 
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function, with variable values for bottom, top and slope. The curve fitting is implemented using 
Pipeline Pilot's dose-response component (giving similar results to similar tools such as 
GraphPad's Prism and IDBS's XlFit). 
Cytopathic Effect. HaCat keratinocyte cells were cultured in freshly prepared growth media 
(including 10 mL of Dulbecco's Modified Eagle's medium (DMEM) supplemented with 3.7 
g/L sodium bicarbonate, and 10% heat inactivated foetal bovine serum. HaCaT cells were 
incubated overnight in 96-well plates at a concentration of 1 × 104 cells per well, to allow cell 
adhesion. Cells were treated with concentration range of 0-256 μg mL-1 for complexes 4-7, 11, 
12 and 14 in 200 μL of growth medium at 37 oC with 5% CO2. The cytopathic effect was 
checked every hour under microscopy.  
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Table S1. Crystallographic Data for Complexes 1 and 4 
  1 4 
Formula C14H26Cl2IrN5 C29H32ClIrN5 
FW 527.50 683.64 
Temp (K) 150(2) 150(2) 
Crystal system monoclinic triclinic 
Space group P21/c P-1 
a (Å) 13.09904(18) 9.80400(17) 
b (Å) 7.96973(11) 15.8991(2) 
c (Å) 17.6195(2) 18.4457(3) 
α (º) 90 82.7271(13) 
β (º) 92.2718(14) 86.7456(14) 
γ (º) 90 72.2390(14) 
Volume (Å3) 1837.95(4) 2715.64(8) 
Z 4 4 
Dcalc(mg/cm3) 1.906 1.672 
μ(mm-1) 7.559 5.043 
F(000) 1024.0 1350.0 
Crystal size (mm3) 
0.35 × 0.35 × 0.08 
orange block 
0.5 × 0.13 × 0.038 
brown block 
Reflections measured 29267 83915 
Indep reflection 6136 18356 
R1 [I>2σ(I)] 0.0258 0.0330 
wR2 (all data) 0.0903 0.0751 
CCDC deposit no 1846267 1846268 
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Table S2. Hydrogen Bond Lengths (Å) and Angles (o) for Complex 1 
D-H           H...A         D...A         <(DHA)  
0.88 2.56 3.344(3) 148.8 N4-H4...Cl2_$1 
0.88 2.35 3.189(4) 158.9 N6-H6B...Cl2_$1 
0.88 2.58 3.361(3) 148.0 N5-H5...Cl2 
0.88 2.46 3.268(4) 152.4 N6-H6A...Cl2 
 
 
 
Table S3. Hydrogen Bond Lengths (Å) and Angles (o) for Complex 4 
D-H           H...A         D...A         <(DHA)  
0.88 2.43 3.273(3) 161.8 N107-H10A_b...Cl1 
0.88 2.54 3.375(3) 157.8 N108-H108...Cl1 
0.88 2.00 2.838(9) 157.9 N110-H11A...O01_$1b 
0.88 2.49 3.294(4) 152.7 N110-H11B...Cl2_$2 
0.88 2.41 3.243(3) 158.4 N207-H207...Cl1 
0.88 2.46 3.303(3) 161.2 N208-H208...Cl1 
0.88 2.39 3.218(3) 157.1 N210-H21A...Cl2 
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Table S4. Antimicrobial Activity of IrIII Complexes 1-14 as MICs (µg/mL; μM in brackets), and 
HPLC retention times 
Comp. MRSAa E. coli 
K. 
pneumoniae 
P. 
aeruginosa 
A. baumanii 
C. 
albicans 
C. 
neoformans 
R-T (min)c 
1 
32 
(59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
>32 
(>59.7) 
13.0±1.4 
2 
16 
(27.2) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
>32 
(>54.3) 
14.4±0.6 
3 
4 
(6.3) 
16 
(25) 
>32 
(>50) 
>32 
(>50) 
32 
(>50) 
4 
(6.3) 
4 
(6.3) 
17.8±0.3 
4 
1 
(1.5) 
4 
(5.8) 
32 
(46.6) 
32 
(46.6) 
4 
(5.8) 
1 
(1.5) 
0.25 
(0.4) 
25.2±1.1 
5 
1 
(1.4) 
8 
(11.2) 
>32 
(>44.8) 
>32 
(>44.8) 
4 
(5.6) 
1 
(1.4) 
0.25 
(0.4) 
23.4±0.3 
6 
1 
(1.3) 
4 
(5.4) 
16 
(21.6) 
32 
(43.2) 
4 
(5.4) 
1 
(1.3) 
0.25 
(0.3) 
22.6±0.3 
7 
1 
(1.4) 
4 
(5.5) 
32 
(44) 
>32 
(>44) 
4 
(5.5) 
1 
(1.4) 
0.5 
(0.7) 
22.5±0.3 
8 
1 
(1.2) 
8 
(9.3) 
8 
(9.3) 
>32 
(>37.2) 
4 
(4.7) 
1 
(1.2) 
0.5 
(0.6) 
20.93±0.02 
9 
1 
(1.1) 
8 
(8.8) 
16 
(17.6) 
>32 
(>35) 
16 
(17.6) 
1 
(1.1) 
0.5 
(0.6) 
20.95±0.02 
10 
1 
(1.2) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
2 
(2.4) 
1 
(1.2) 
21.44±0.07 
11 
1 
(1.1) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
2 
(2.2) 
2 
(2.2) 
32.2±0.1 
12 
1 
(1.2) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
2 
(2.4) 
2 
(2.4) 
36.93±0.08 
13 
1 
(1.2) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
>32 
(>38) 
2 
(2.4) 
1 
(1.2) 
34.89±0.02 
14 
1 
(1.1) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
>32 
(>35) 
2 
(2.2) 
1 
(1.1) 
32.42±0.01 
Colb 
>32 
(>27.7) 
0.125 
(0.11) 
0.125 
(0.11) 
0.25 
(0.22) 
0.25 
(0.22) 
>32 
(>27.7) 
32 
(27.7) 
n. d. 
Van 
1 
(0.7) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
>32 
(>22) 
n. d. 
Flu 
>32 
(>104) 
>32 
(>104) 
>32 
(>104) 
>32 
(>104) 
>32 
(>104) 
0.125 
(0.41) 
8 
(26) 
n. d. 
aBacterial strains: MRSA: ATCC 43300; E. coli, ATCC 25922; MDR K. pneumoniae, ATCC 700603; 
P. aeruginosa, ATCC 27853; A. baumannii, ATCC 19606. Fungus strains: C. albicans, ATCC 90028; 
C. neoformans, ATCC 208821. bModel antibiotics: colistin (Col) and vancomycin (Van) as antibacterial 
agents; fluconazole (Flu) as antifungal agent; cR-T: retention time by RP-HPLC. 
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Table S5. Antibacterial Activity (MICs, µg/mL) of Complexes 4-10 against S. aureus and S. 
pyogenes under Anaerobic and Aerobic Conditions 
Complex 
S. aureus S. pyogenes 
anaerobic aerobic anaerobic aerobic 
4 2 2 0.5 0.25 
5 2 2 0.5 0.25 
6 2 2 0.5 0.125 
7 2 1 0.5 0.125 
8 2 0.5 1 0.25 
9 2 0.5 1 0.25 
10 2 0.5 1 0.25 
 
Table S6. Selectivity Factors (SF) for Complexes 4-14 against HEK-293 (CC50/MBC) Cells and 
RBC (HC50/MBC in brackets) versus Bactericidal Activity against Gram-positive bacteria (MBC) 
from Table S5 
Complex S. aureus B. subtilis S. pyogenes S. epidermidis E. faecalis 
 SF : CC50/MBC (HC50/MBC) 
4 >16 (3) >64 (12) >32 (6) >64 (12) >4 (0.8) 
5 >16 (6) >64 (24) >128 (42) >64 (24) >4 (1.5) 
6 9 (10) 9 (11) 34 (42) 69 (84) 17 (0.7) 
7 >32 (7) >64 (29) >256 (118) >64 (29) >8 (4) 
8 24 (7) 24 (7) 95 (27) 24 (7)  0.7 (0.2) 
9 4 (2) 17 (8) 68 (29) 34 (17) 1.1 (5) 
10 n.d. >2 (0.9) >128 (57) n.d. n.d. 
11 n.d. >2 (>2) >16 (>16) n.d. n.d. 
12 n.d. >1 (>1) >4 (>4) n.d. n.d. 
13 n.d. >2 (>1) >4 (3) n.d. n.d. 
14 n.d. >1 (>1) >8 (>8) n.d. n.d. 
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Table S7. Dependence of Antibacterial Activity of Complexes 4-10 as MICs (µg/mL) on Time of 
Storage of Solutions of Complexes in CAMH Broth Medium at Various Temperatures (18 to +42 
oC) from 1-21 Days 
Complex 
Day 1 Day 4 Day 8 Day 21 
-18 oC 18 oC 42 oC -18 oC 18 oC 42 oC 42 oC 42 oC 
4 2 2 2 2 1 2 2 4 
5 2 2 2 2 1 4 1 4 
6 2 2 2 2 1 4 8 4 
7 2 2 1 2 2 2 2 4 
8 4 2 1 1 4 2 4 16 
9 2 2 1 2 1 1 2 8 
10 2 1 1 2 2 4 8 32 
 
 
Table S8. S. aureus Biofilm Disruption (log cell number) by Complexes 4-9 at Various 
Concentrations (2-100 μg/mL) 
Complex 
Complex Concentration (μg/mL) Negative 
Control 100 50 30 20 10 5 2 
log (cell number)  
4 3.33±0.35 3.73±0.05 7.40±0.02 8.10±0.19 8.84±0.06 8.92±0.08 9.07±0.11 
9.13±0.11 
5 3.40±0.17 3.97±0.07 7.35±0.04 7.99±0.08 8.59±0.11 8.81±0.29 8.86±0.09 
6 3.91±0.12 4.09±0.09 7.44±0.03 8.16±0.11 8.89±0.11 8.88±0.03 8.96±0.10 
7 3.61±0.39 4.05±0.02 7.12±0.07 8.03±0.12 8.78±0.15 8.77±0.21 8.80±0.04 
8 3.89±0.21 4.98±0.09 7.42±0.11 8.14±0.14 8.76±0.15 9.17±0.11 8.93±0.08 
9 3.85±0.14 6.11±0.07 7.86±0.09 8.22±0.09 8.74±0.24 8.99±0.09 8.90±0.05 
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Table S9. Results of ANOVA for the Difference in Numbers of Bacteria after Treatment with 
Various Concentrations of Complexes and for Negative Controls (see Figure 4).3 
 Df  Sum Sq Mean Sq F value Pr (>F) 
complex 5 23.9 4.8 44.10 <2e-16 *** 
concentration 6 2779.6 463.3 4281.14 <2e-16 *** 
complex: concentration 30 54.5 1.8 16.79 <2e-16 *** 
residuals 84 9.1 0.1   
There are statistically significant effects of complex and concentration numbers of bacteria, 
and the effect of concentration differs between the complexes (Significant interaction). 
 
Table S10. MBC/MIC Ratio of for Complexes 1-14 against Gram-positive Bacteria. 
Complex S. aureus B. subtilis S. pyogenes S. epidermidis E. faecalis 
1 n.d. n.d. 4 4 n.d. 
2 2 2 2 2 4 
3 1 1 1 4 4 
4 1 1 4 2 8 
5 1 1 1 1 8 
6 1 2 4 1 32 
7 2 2 1 1 4 
8 2 2 1 2 64 
9 8 4 1 1 16 
10 >64 32 1 >128 n.d. 
11 >64 32 2 >64 n.d. 
12 >64 32 8 >128 n.d. 
13 >64 32 16 >128 n.d. 
14 >64 64 4 >128 n.d. 
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Figure S1. Elution conditions for determination of relative hydrophobicity measurements by 
RP-HPLC. Solvent A: H2O 50 mM NaCl; Solvent B: H2O/CH3CN 1:1 50 mM NaCl. 
 
 
Figure S2. Plot of retention time (min) versus MICs (μM) for complexes 1-4 against MRSA. 
It is evident that the antibacterial activity of complexes increases with increase of the RP-HPLC 
retention times. The hydrophobicity of the substituent on the CpX ring increases from Me to Ph 
to biphenyl in complexes 1, 2 and 3, respectively, and complex 4 also has the biphenyl 
substituent (Chart 2). 
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Figure S3. Reaction of complex 4 (2 mM in 20% DMSO-d6/80% D2O) with L-cysteine (1 mol 
equiv) monitored by 1H NMR at 37 oC, pH* 7.1. 
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Figure S4. Reaction of complex 7 (2 mM in 20% DMSO-d6/80% D2O) with L-cysteine (1 mol 
equiv) monitored by 1H NMR at 37 oC, pH* 7.1. 
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Figure S5. Reaction of complexes 4, 7 and 10 (2 mM, MeOH/H2O, 2:3 (v/v)) with L-cysteine 
(2 mM, H2O, L-Cys) monitored by LC-MS after 24 h incubation at 37 
oC, pH 7.1 ± 0.1. The 
dinuclear bridged complex [(CpXbiph)Ir(L-Cys)]2
2+ (P2, detected by MS as [(CpXbiph)Ir(L-Cys)-
H]2
+) is the major product after 24 h with concomitant release of free biguanide ligand. 
 
Figure S6. LC-MS gradients for identification of [(CpXbiph)Ir(L-Cys)]2
2+ from the reaction of 
complexes 4, 7 and 10 with L-Cys using H2O with 0.1% formic acid (v/v, FA) (Solvent A) and 
CH3CN with 0.1% FA (v/v) (solvent B) as eluents. Column type: ZORBAX Eclipse XDB-C18, 
9.4 × 250 mm, 5 µm. 
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Figure S7. Dependence of chemical shift of low field 1H NMR resonances (tolyl proton) of the 
ligands L5 (1-(o-tolyl)Big) and L6 (TolSul-Big-Tol) in 20% MeOD-d4 /80% D2O on pH* over 
the range 2-14. The solid lines are the best fits corresponding to pKa* values of above 12 and 
4.7 ± 0.1 for L5 and L6, respectively.  
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